TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex - PubMed (original) (raw)
. 1996 Jul 12;271(28):16603-8.
doi: 10.1074/jbc.271.28.16603.
Affiliations
- PMID: 8663147
- DOI: 10.1074/jbc.271.28.16603
Free article
TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex
L Bajzar et al. J Biol Chem. 1996.
Free article
Abstract
TAFI (thrombin-activatable fibrinolysis inhibitor) is a recently discovered plasma protein that can be activated by thrombin-catalyzed proteolysis to a carboxypeptidase B-like enzyme that inhibits fibrinolysis. This work shows that the thrombin-thrombomodulin complex, rather than free thrombin, is the most likely physiologic activator. Thrombomodulin increases the catalytic efficiency of the reaction by a factor of 1250, an effect expressed almost exclusively through an increase in kcat. The kinetics of the reaction conform to a model whereby thrombin can interact with either TAFI (Km = 1.0 microM) or thrombomodulin (Kd = 8.6 nM), and either binary complex so formed can then interact with the third component to form the ternary thrombin-thrombomodulin-TAFI complex from which activated TAFI is produced with kcat = 1.2 s-1. This work also shows that activated TAFI down-regulates tPA-induced fibrinolysis half-maximally at a concentration of 1.0 nM in a system of purified components. This concentration of TAFI is about 2% of the level of the zymogen in plasma, which indicates that ample activated TAFI could be generated to very significantly modulate fibrinolysis in vivo. Therefore, TAFI in vitro and possibly in vivo defines an explicit molecular connection between the coagulation and fibrinolytic cascades, such that expression of activity in the former down-regulates the activity of the latter.
Similar articles
- Thrombin, thrombomodulin and TAFI in the molecular link between coagulation and fibrinolysis.
Nesheim M, Wang W, Boffa M, Nagashima M, Morser J, Bajzar L. Nesheim M, et al. Thromb Haemost. 1997 Jul;78(1):386-91. Thromb Haemost. 1997. PMID: 9198184 Review. - Both cellular and soluble forms of thrombomodulin inhibit fibrinolysis by potentiating the activation of thrombin-activable fibrinolysis inhibitor.
Bajzar L, Nesheim M, Morser J, Tracy PB. Bajzar L, et al. J Biol Chem. 1998 Jan 30;273(5):2792-8. doi: 10.1074/jbc.273.5.2792. J Biol Chem. 1998. PMID: 9446587 - Thrombin-activatable fibrinolysis inhibitor antigen and TAFI activity in patients with APC resistance caused by factor V Leiden mutation.
Antovic JP, Blombäck M. Antovic JP, et al. Thromb Res. 2002 Apr 1;106(1):59-62. doi: 10.1016/s0049-3848(02)00072-5. Thromb Res. 2002. PMID: 12165290 - Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U).
Bouma BN, Marx PF, Mosnier LO, Meijers JC. Bouma BN, et al. Thromb Res. 2001 Mar 1;101(5):329-54. doi: 10.1016/s0049-3848(00)00411-4. Thromb Res. 2001. PMID: 11297751 Review.
Cited by
- Novel Deep Sea Isoindole Alkaloid FGFC1 Exhibits Its Fibrinolytic Effects by Inhibiting Thrombin-Activatable Fibrinolysis Inhibitor.
Zhang H, Diao X, Jiang T, Wei M, Su Y, Shen J, Bao C, Wu W. Zhang H, et al. Pharmaceuticals (Basel). 2024 Oct 20;17(10):1401. doi: 10.3390/ph17101401. Pharmaceuticals (Basel). 2024. PMID: 39459040 Free PMC article. - Identification of heparin interaction sites on thrombin-activatable fibrinolysis inhibitor that modulate plasmin-mediated activation, thermal stability, and antifibrinolytic potential.
Marar TT, Boffa MB. Marar TT, et al. Res Pract Thromb Haemost. 2024 May 27;8(4):102459. doi: 10.1016/j.rpth.2024.102459. eCollection 2024 May. Res Pract Thromb Haemost. 2024. PMID: 38983903 Free PMC article. - Fibrinolysis biomarker, thrombin, and activated protein C level alterations after coagulation activation depend on type of thrombophilia and clinical phenotype.
Reda S, Schwarz N, Müller J, McRae HL, Oldenburg J, Pötzsch B, Rühl H. Reda S, et al. Res Pract Thromb Haemost. 2024 Feb 15;8(2):102351. doi: 10.1016/j.rpth.2024.102351. eCollection 2024 Feb. Res Pract Thromb Haemost. 2024. PMID: 38487678 Free PMC article. - Coagulofibrinolytic effects of recombinant soluble thrombomodulin in prolonged porcine cardiac arrest.
Zhang B, McCracken BM, Mahmood CC, Leander D, Greer N, Cranford JA, Hsu CH, Tiba MH, Neumar RW, Greineder CF. Zhang B, et al. Resusc Plus. 2023 Sep 27;16:100477. doi: 10.1016/j.resplu.2023.100477. eCollection 2023 Dec. Resusc Plus. 2023. PMID: 37811363 Free PMC article. - The Fibrinolytic System and Its Measurement: History, Current Uses and Future Directions for Diagnosis and Treatment.
Hvas CL, Larsen JB. Hvas CL, et al. Int J Mol Sci. 2023 Sep 16;24(18):14179. doi: 10.3390/ijms241814179. Int J Mol Sci. 2023. PMID: 37762481 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources